As we previously foreshadowed, the innovation patent system has been given its end dates: 25 August 2021: last date to...
Mark Your Calendars: The End of the AU Innovation Patent System is Set
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast™: w/e 21 February 2020
Significant biosimilar activities this week include 12 Feb 20 | Wockhardt announced divestment of assets to Dr...
BioPharma Reporter reports AbbVie defence strategy for Humira
On 18 Feb 2020, BioPharma Reporter reported that AbbVie had outlined its defence strategy for Humira (adalimumab)...
Pearce IP BioBlast™: f/e 07 February 2020
Significant biosimilar activities this fortnight include 05 Feb 20 | Merck announced a new spin-off company which will...
Pearce IP BioBlast™: w/e 24 January 2020
Significant biosimilar activities this week include Jan 20 | Genentech and Roche commenced recruitment for Ph III...
The innovation patent system is nearing its end
The Intellectual Property Laws Amendment (Productivity Commission Response Part 2 and Other Measures) Bill 2019 clears...
New Zealand Introduces Excess Claims Fee in Patent Examination
The Intellectual Property Office of New Zealand (IPONZ) has announced the introduction of excess claims fee, an...
R’mAb AU: “step down” inj’n saved for another day – short, fixed term, blanket injunction for Sandoz
Today the Federal Court ordered an interlocutory injunction against Sandoz, restraining it from selling biosimilar...
Remicade™ Biosimilars US: Key Remicade™ patent revoked by Fed Cir
J&J suffered another blow today as a key Remicade® (infliximab) patent was revoked by US Court of Appeals (Federal...
Remicade™ Biosimilars US: Pfizer sues J&J for anticompetitive conduct
Biosimilar development is not for the faint hearted. The time and costs involved in R&D, clinical, and regulatory...
First wave of patent reform in AU: consultation period ends 17 Nov 2017
IP Australia is inviting submissions by 17 November 2017 on the first wave of IP reform initiatives arising from...
Medicines for Europe Issues 2017 Biosimilar Market Review
Eleven years after the launch of the first biosimilar product in EU, we are now in a position to calibrate our...
Case Note: Humira™case confirms no AU PTE for swiss style claims
In a case relating to patents for global blockbuster biologic Humira™ (Adalimumab), the Full Federal Court has drawn a...
Green light for patent reform in Australia
This afternoon, the Australian Government released its response to the report of the Productivity...
Amgen v Hospira: BPCIA dance lessons in the Federal Circuit
Just over a week ago, the US Federal Circuit provided BPCIA “dance lessons” for reference product sponsors and...
TGA seeks input on biosimilar naming in Australia
The TGA consultation paper can be found here. The TGA paper outlines the biosimilar naming conventions implemented in...